Toll Brothers Inc. (NYSE:TOL) shares increased 0.15% in last trading session and ended the day at $33.88. TOL Gross Margin is 21.60% and its has a return on assets of 4.20%. Toll Brothers Inc. (NYSE:TOL) quarterly performance is -4.88%.
Credit Suisse reiterated their outperform rating on shares of Toll Brothers Inc (NYSE:TOL) in a research note issued to investors on Wednesday, Market Beat reports. The firm currently has a $40.00 price target on the stock.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) ended the last trading day at $30.85. Company weekly volatility is calculated as 12.63% and price to cash ratio as 5.50. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) showed a weekly performance of 105.94%.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced that its Phase 3 EASE LID clinical trial evaluating the company’s investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease met its primary endpoint. Results from this randomized, placebo-controlled study showed a statistically significant reduction (p = 0.0009) in LID at 12 weeks for patients who received ADS-5102 versus placebo as assessed by the Unified Dyskinesia Rating Scale (UDysRS).
On 23 December, Mobileye N.V. (NYSE:MBLY) shares increased 4.58% and was closed at $41.32. Mobileye N.V. (NYSE:MBLY) year to date (YTD) performance is 1.87%.
Mobileye N.V. (NYSE:MBLY) announced that Professor Amnon Shashua, the Company’s co-founder, chairman and CTO, is scheduled to make a presentation at CES on Wednesday, January 6, 2016 at 10:30am PST. Professor Shashua will reveal our plans for future technology expansion, and provide more details about our enhanced roadmap, especially focused on autonomous driving.
Avinger, Inc. (NASDAQ:AVGR) shares increased 12.52% in last trading session and ended the day at $22.74. AVGR Gross Margin is 43.10% and its has a return on assets of -74.40%. Avinger, Inc. (NASDAQ:AVGR) quarterly performance is 51.70%.
On December 17, 2015, Avinger, Inc. (NASDAQ:AVGR) board of directors appointed James G. Cullen to its Audit Committee. Mr. Cullen has been one of our directors since December 2014 and was formerly a director and the chairman of the audit committee of Johnson & Johnson. Mr. Cullen replaces Dr. John B. Simpson on Audit Committee effective as of December 17, 2015.
Genocea Biosciences, Inc. (NASDAQ:GNCA) caters to the Healthcare space. Its weekly performance is -0.62%. On the last day of trading company shares ended up at $6.39. Genocea Biosciences, Inc. (NASDAQ:GNCA) distance from 50-day simple moving average (SMA50) is 4.67%.
On December 17, 2015, Genocea Biosciences, Inc. (NASDAQ:GNCA) entered into the first amendment (the “First Amendment”) to the Loan and Security Agreement by and between Hercules Technology Growth Capital, Inc. (“Hercules”) and the Company, dated as of November 20, 2014 (as amended by the First Amendment, the “Loan Agreement”). Pursuant to the Loan Agreement, the Company may borrow term loan facilities of up to $27.0 million (the “Term Loans”) comprised of a term loan in an aggregate principal amount of up to Twelve Million Dollars and term loans (each a “Term B Loan Advance”) in an aggregate principal amount of up to Fifteen Million Dollars. Each Term B Loan Advance will be available in increments of $5.0 million dollars upon the achievement of certain milestones for certain limited periods of time.
Leave a Reply